Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21704935 | 1.00 | JAK3 (0.61) | JAK3BTK | |
| SCHEMBL21704957 | 0.98 | JAK3 (0.61) | JAK3BTK | |
| SCHEMBL21701287 | 0.98 | JAK3 (0.61) | JAK3BTK | |
| SCHEMBL21701282 | 0.97 | JAK3 (0.61) | JAK3BTK | |
| SCHEMBL21705167 | 0.97 | JAK3 (0.61) | JAK3BTK | |
| SCHEMBL16765329 | 0.89 | JAK3 (0.72) | JAK3BTK | |
| SCHEMBL16765330 | 0.89 | JAK3 (0.72) | JAK3BTK | |
| SCHEMBL16765640 | 0.89 | JAK3 (0.77) | JAK3BTK | |
| SCHEMBL16765641 | 0.89 | JAK3 (0.77) | JAK3BTK | |
| SCHEMBL21701281 | 0.88 | JAK3 (0.67) | JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035373-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS | ACLARIS THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12297203-B2 | Pyrrolopyrimidine ITK inhibitors | ACLARIS THERAPEUTICS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| CN-119080779-A | Pyrrolopyrimidine ITK inhibitors | 阿克拉瑞斯治疗股份有限公司 | 2024-12-06 | — | — | CN | disclosed |
| CN-112823005-B | Pyrrolopyrimidine ITK inhibitors | 阿克拉瑞斯治疗股份有限公司 | 2024-08-20 | — | — | CN | disclosed |
| US-11820775-B2 | Pyrrolopyrimidine ITK inhibitors | ACLARIS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820775-B2 | Pyrrolopyrimidine ITK inhibitors | ACLARIS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820775-B2 | Pyrrolopyrimidine ITK inhibitors | ACLARIS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20220348579-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS | ACLARIS THERAPEUTICS, INC. | 2022-11-03 | — | — | US | disclosed |
| US-11021482-B2 | Pyrrolopyrimidine ITK inhibitors | Adaris Therapeutics, Inc. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200048262-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS | ACLARIS THERAPEUTICS, INC. | 2020-02-13 | — | — | US | disclosed |
| WO-2020033955-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS | ACLARIS THERAPEUTICS, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035373-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS | JAK3, JAK1, JAK2 | JAK3 1/4885BTK 46/4885 |
| US-20200048262-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS | ITK, PDXK, DMPK | JAK3 1484/4885BTK 558/4885 |
| US-12297203-B2 | Pyrrolopyrimidine ITK inhibitors | ITK, PDXK, DMPK | JAK3 1484/4885BTK 558/4885 |
| US-20220348579-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS | ITK, PDXK, DMPK | JAK3 1484/4885BTK 558/4885 |
| US-11021482-B2 | Pyrrolopyrimidine ITK inhibitors | ITK, PDXK, DMPK | JAK3 1484/4885BTK 558/4885 |
| US-11820775-B2 | Pyrrolopyrimidine ITK inhibitors | ITK, PDXK, DMPK | JAK3 1484/4885BTK 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.